Latest Content

Clesrovimab remained well tolerated through a second RSV season in infants at increased risk of severe RSV.

The Pharmacy Compounding Advisory Committee meets July 23-24 to discuss whether pharmacies may dispense BPC-157, TB-500, and 5 other peptides.

Dermatologists spend 13 hours weekly on prior authorization as health plans tout an 11% reduction in requests.

Use of automated insulin delivery technology improves a Healthcare Effectiveness Data and Information Set quality measure in individuals with type 2 diabetes.

Eplontersen added to standard of care did not significantly reduce cardiovascular death and recurrent events, a study finds.

Trump said imported generic drugs will face no tariff for 2 years starting August 1, then a 100% rate in 2028 and 200% in 2029, extending his trade fight to the drugs most Americans actually take.

New York City health officials confirmed a 5th fatality in the Upper East Side Legionnaires' disease outbreak.

This research reinforces that fixed-duration, chemotherapy-free regimens can offer both a tolerability and a patient-experience advantage over CIT.

FDA approves zidesamtinib for ROS1-positive NSCLC after prior TKIs, offering a new option for resistant and CNS-active disease.